Toxicity Concern for the Radiopharmaceuticals for the Diagnosis of Alzheimer's Disease.

Abstract

This editorial discusses the toxicity and ethical concerns associated with the utilization of radiopharmaceuticals for diagnosing Alzheimer's disease. It highlights the potential benefits of using amyloid tracers during the early stages of diagnosing the disease. However, it also raises ethical concerns regarding the communication of this data to patients as well as their families. Additionally, it addresses the toxicity concerns associated with different radiopharmaceuticals, elucidating their potential to accumulate in bone and pose risks to the kidneys and bone marrow. We have examined the negative consequences, such as blood-related toxicity and suppression of bone marrow function, which have been recorded for different radiopharmaceuticals.